Sysmex, Eisai Team Up For Alzheimer’s Diagnostics
Executive Summary
Sysmex is teaming up with fellow Japanese pharma company Eisai to develop a new generation of diagnostic reagents for dementia, including Alzheimer’s disease, which is projected to affect an estimated 65.7 million people globally by 2030 according to the World Health Organization. The companies have entered into a non-exclusive collaboration to create novel IVD products that will enable early detection as well as help physicians in treatment selection and effectiveness monitoring.